Loading...
Market
What will be the regulatory approval status of lenacapavir in the first country by end of 2024?
2
Resolution / Starting Odds
Approved for prevention • 25%
Approved for treatment • 25%
Approved for both prevention and treatment • 25%
Not approved • 25%
Regulatory approval announcements from health authorities in the respective countries
Story
Gilead Signs Royalty-Free Deals with Six Generics for Investigational HIV Drug Lenacapavir in 120 Countries
Oct 2, 2024, 01:35 PM
Gilead Sciences has signed non-exclusive, royalty-free voluntary licensing agreements with six generic pharmaceutical manufacturers, including Dr. Reddy's Laboratories and Hetero, to enable access to its investigational HIV prevention medication, lenacapavir, across 120 high-incidence, resource-limited countries. Lenacapavir, pending regulatory approval, is a twice-yearly injectable drug used for HIV-1 prevention and treatment in heavily treatment-experienced adults. The agreements aim to increase global access to this groundbreaking medication, accelerating the global HIV response.
View original story
Similar markets
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Not approved in USA or EU • 25%
United States • 25%
European Union • 25%
South Africa • 25%
Other • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
United States • 25%
South Africa • 25%
India • 25%
Other • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
USA • 25%
UK • 25%
South Africa • 25%
Other • 25%
North America • 25%
Europe • 25%
Africa • 25%
Asia • 25%
